Építés alatt – nem éles oldal
Belépés

NCT03553875Leállítva3. fázis

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. febr. 25.

Megadott ok: requested by the IRB

Rövid összefoglaló (regiszter, angolul)

This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18. This study consists of up to 6 visits to Massachusetts General Hospital.

Állapot (regiszter)
Leállítva
Fázis (regiszter)
3. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
25 (tényleges)
Első benyújtás
2018. jún. 1.
Kezdés
2018. nov. 13.
Elsődleges befejezés
2025. nov. 25.
Fő szponzor
Massachusetts General Hospital
NCT-szám
NCT03553875

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Subjects currently treated with the following medications (known to impact glutamate levels): Lamotrigine, Amantadine, N-acetylcysteine, D-cycloserine
  • Subjects treated with a psychotropic medication not listed above on a dose that has not been stable for at least 4 weeks prior to study baseline.
  • Co-administration of drugs that compete with memantine for renal elimination using the same renal cationic system, including hydrochlorothiazide, triamterene, metformin, cimetidine, ranitidine, quinidine, and nicotine
  • Initiation of a new psychosocial intervention within 30 days prior to randomization.
  • Subjects who meet on the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-E) for alcohol or drug dependence or abuse. If the subject has a recent history of substance abuse, there will be a two-week washout period before initiating the trial as an added precaution. There are no known safety issues relating to memantine and recent history of substance abuse.

Más betegség

  • Subjects with a history of non-febrile seizures without a clear and resolved etiology.
  • Subjects with a history of or a current liver or kidney disease.
  • Clinically unstable psychiatric conditions or judged to be at serious suicidal risk.
  • Serious, stable or unstable systemic illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
  • Subjects with genitourinary conditions that raise urine pH (e.g., renal tubular acidosis, severe infection of the urinary tract).
  • Known hypersensitivity to memantine.
  • Severe allergies or multiple adverse drug reactions.
  • A history of intolerance or adequate exposure to memantine, as determined by the clinician.

Laborértékek

  • Subjects with severe hepatic impairment (LFTs > 3 times ULN).

Egyéb

  • IQ ≤70 based on the Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary and Matrix Reasoning subtests
  • Impaired communicative speech
  • Subjects who are pregnant and/or nursing.
  • Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild.

Kiket keres a vizsgálat

  • Male \& female subjects ages 8-18 years (inclusive).
  • Diagnostic Statistical Manual (DSM)-5 Autism Spectrum Disorder (ASD) diagnostic criteria as established by clinical diagnostic interview
  • At least moderate severity of social impairment as measured by a total raw score of ≥85 on the parent/guardian-completed Social Responsiveness Scale-Second Edition (SRS-2)14 and a score of ≥4 on the clinician-administered Clinical Global Impression-Severity scale (CGI-S)17.

Életkor a regiszterben: 8 év – 18 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Massachusetts General HospitalBostonEgyesült ÁllamokIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.